SIR and EAR of invasive SMN among 5-year survivors of childhood Hodgkin lymphoma
| Second cancer diagnosis . | Observed . | Expected . | SIR . | 95% CI . | EAR/10 000 PY . | 95% CI . |
|---|---|---|---|---|---|---|
| All SMN | 277 | 31.9 | 8.7 | 7.7-9.8 | 69.2 | 60.3-79.3 |
| Males | 82 | 13.0 | 6.3 | 5.0-8.0 | 37.0 | 27.9-48.4 |
| Females | 195 | 18.9 | 10.3 | 8.9-11.8 | 105.1 | 89.8-122.7 |
| Hematopoietic | ||||||
| Leukemia | 13 | 1.0 | 12.7 | 7.4-21.9 | 3.4 | 1.8-6.0 |
| Non-Hodgkin lymphoma | 15 | 1.9 | 8.1 | 4.6-14.3 | 3.7 | 1.9-7.0 |
| Solid tumors | ||||||
| Breast | 109 | 6.4 | 17.0 | 14.0-21.7 | 29.0 | 23.5-35.7 |
| Thyroid | 42 | 2.4 | 17.6 | 13.0-24.0 | 11.2 | 8.1-15.5 |
| Head and neck | 10 | 0.9 | 11.7 | 6.3-21.7 | 2.6 | 1.3-5.0 |
| Lung/bronchus | 7 | 1.1 | 6.3 | 3.0-13.2 | 1.7 | 0.6-3.8 |
| Small intestine/colorectal | 11 | 1.7 | 6.6 | 3.7-12.0 | 2.6 | 1.3-5.1 |
| Bone cancer | 6 | 0.3 | 22.3 | 10.0-49.6 | 1.6 | 0.7-3.7 |
| Soft tissue sarcomas | 22 | 2.0 | 10.9 | 7.2-16.3 | 5.6 | 3.5-8.9 |
| CNS | 7 | 1.2 | 6.1 | 2.9-12.7 | 1.7 | 0.6-3.8 |
| Kidney | 5 | 0.7 | 7.2 | 3.0-17.3 | 1.2 | 0.4-3.2 |
| Melanoma | 13 | 3.3 | 4.0 | 2.3-6.8 | 2.8 | 1.2-5.4 |
| Female genital | 4 | 3.0 | 1.3 | 0.5-3.54 | 0.3 | −0.4-2.2 |
| Others | 12 | 4.5 | 2.7 | 1.5-4.7 | 2.1 | 0.6-4.7 |
| Second cancer diagnosis . | Observed . | Expected . | SIR . | 95% CI . | EAR/10 000 PY . | 95% CI . |
|---|---|---|---|---|---|---|
| All SMN | 277 | 31.9 | 8.7 | 7.7-9.8 | 69.2 | 60.3-79.3 |
| Males | 82 | 13.0 | 6.3 | 5.0-8.0 | 37.0 | 27.9-48.4 |
| Females | 195 | 18.9 | 10.3 | 8.9-11.8 | 105.1 | 89.8-122.7 |
| Hematopoietic | ||||||
| Leukemia | 13 | 1.0 | 12.7 | 7.4-21.9 | 3.4 | 1.8-6.0 |
| Non-Hodgkin lymphoma | 15 | 1.9 | 8.1 | 4.6-14.3 | 3.7 | 1.9-7.0 |
| Solid tumors | ||||||
| Breast | 109 | 6.4 | 17.0 | 14.0-21.7 | 29.0 | 23.5-35.7 |
| Thyroid | 42 | 2.4 | 17.6 | 13.0-24.0 | 11.2 | 8.1-15.5 |
| Head and neck | 10 | 0.9 | 11.7 | 6.3-21.7 | 2.6 | 1.3-5.0 |
| Lung/bronchus | 7 | 1.1 | 6.3 | 3.0-13.2 | 1.7 | 0.6-3.8 |
| Small intestine/colorectal | 11 | 1.7 | 6.6 | 3.7-12.0 | 2.6 | 1.3-5.1 |
| Bone cancer | 6 | 0.3 | 22.3 | 10.0-49.6 | 1.6 | 0.7-3.7 |
| Soft tissue sarcomas | 22 | 2.0 | 10.9 | 7.2-16.3 | 5.6 | 3.5-8.9 |
| CNS | 7 | 1.2 | 6.1 | 2.9-12.7 | 1.7 | 0.6-3.8 |
| Kidney | 5 | 0.7 | 7.2 | 3.0-17.3 | 1.2 | 0.4-3.2 |
| Melanoma | 13 | 3.3 | 4.0 | 2.3-6.8 | 2.8 | 1.2-5.4 |
| Female genital | 4 | 3.0 | 1.3 | 0.5-3.54 | 0.3 | −0.4-2.2 |
| Others | 12 | 4.5 | 2.7 | 1.5-4.7 | 2.1 | 0.6-4.7 |
SIR indicates standardized incidence ratio; EAR, excess absolute risk; SMN, second malignant neoplasm; CI, confident interval; PY, person-year; and CNS, central nervous system.